|
| 37529402 | Real-World Analysis of Clinical Characteristics and Survival Outcomes in Patients With Extensive-Stage SCLC Treated With First-Line Chemoimmunotherapy. | JTO Clin Res Rep | 2023 |
| 34562610 | Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy - results from the randomised phase II ETOP/IFCT 4-12 STIMULI trial. | Ann Oncol | 2022 |
| 35404393 | Sunvozertinib, a Selective EGFR Inhibitor for Previously Treated Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations. | Cancer Discov | 2022 |
| 34953676 | NaPi2b expression in a large surgical Non-Small Cell Lung Cancer (NSCLC) cohort. | Clin Lung Cancer | 2022 |
| 35099823 | Loss of STING expression is prognostic in non-small cell lung cancer. | J Surg Oncol | 2022 |
| 34923204 | Impacts of lung cancer multidisciplinary meeting presentation: Drivers and outcomes from a population registry retrospective cohort study. | Lung Cancer | 2022 |
| 32778511 | Impact of Radiotherapy on the Efficacy and Toxicity of anti-PD-1 Inhibitors in Metastatic NSCLC. | Clin Lung Cancer | 2021 |
| 34939294 | Developments in systemic therapies for the management of lung cancer. | Intern Med J | 2021 |
| 34046489 | Excess mortality and undertreatment in elderly lung cancer patients: treatment nihilism in the modern era? | ERJ Open Res | 2021 |
| 34339292 | Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study. | J Clin Oncol | 2021 |
| 34312918 | Do ethnic patients report longer lung cancer intervals than Anglo-Australian patients?: Findings from a prospective, observational cohort study. | Eur J Cancer Care (Engl) | 2021 |
| 33216964 | Relevance of sun safety in patients commencing crizotinib for non-small cell lung cancer. | Australas J Dermatol | 2021 |
| 32193090 | Credentialing of vertebral stereotactic ablative body radiotherapy in a multi-centre trial. | Phys Med | 2020 |
| 31864906 | Occult Gastrointestinal Perforation in a Patient With EGFR-Mutant Non-Small-Cell Lung Cancer Receiving Combination Chemotherapy With Atezolizumab and Bevacizumab: Brief Report. | Clin Lung Cancer | 2020 |
| 32115257 | Reply to the letter-to-the editor "Hospital volume and the case for centralisation of surgical services". | Lung Cancer | 2020 |
| 32540558 | NTRK and ALK rearrangements in malignant pleural mesothelioma, pulmonary neuroendocrine tumours and non-small cell lung cancer. | Lung Cancer | 2020 |
| 30515932 | The Victorian Comprehensive Cancer Centre lung cancer clinical audit: collecting the UK National Lung Cancer Audit data from hospitals in Australia. | Intern Med J | 2019 |
| 31808254 | RET-rearranged non-small-cell lung cancer and therapeutic implications. | Intern Med J | 2019 |
| 31285867 | Standard dose osimertinib for erlotinib refractory T790M-negative <i>EGFR</i>-mutant non-small cell lung cancer with leptomeningeal disease. | J Thorac Dis | 2019 |
| 31445727 | DDR Alterations as a Surrogate Marker for TMB in SCLC - Use it or Lose it? | J Thorac Oncol | 2019 |
| 30797487 | Hospital lung surgery volume and patient outcomes. | Lung Cancer | 2019 |
| 31106127 | Mesenchyme to epithelial transition protein expression, gene copy number and clinical outcome in a large non-small cell lung cancer surgical cohort. | Transl Lung Cancer Res | 2019 |
| 30311110 | Correction to: Differences in cancer survival by sex: a population-based study using cancer registry data. | Cancer Causes Control | 2018 |
| 30194549 | Differences in cancer survival by sex: a population-based study using cancer registry data. | Cancer Causes Control | 2018 |
| 30056857 | BRAF Mutations-A Good News Story for Immune Checkpoint Inhibitors in Oncogene-Addicted NSCLC? | J Thorac Oncol | 2018 |
| 30031382 | The LEAD study protocol: a mixed-method cohort study evaluating the lung cancer diagnostic and pre-treatment pathways of patients from Culturally and Linguistically Diverse (CALD) backgrounds compared to patients from Anglo-Australian backgrounds. | BMC Cancer | 2018 |
| 30705864 | Elderly patients with stage III NSCLC survive longer when chemotherapy is added to radiotherapy-fortune favours the bold. | Transl Lung Cancer Res | 2018 |
| 30429008 | The immune checkpoint, HVEM may contribute to immune escape in non-small cell lung cancer lacking PD-L1 expression. | Lung Cancer | 2018 |
| 28891180 | De novo activating epidermal growth factor mutations (EGFR) in small-cell lung cancer. | Intern Med J | 2017 |
| 28257959 | The Immune Microenvironment, Genome-wide Copy Number Aberrations, and Survival in Mesothelioma. | J Thorac Oncol | 2017 |
| 29208428 | Lung cancer in Asian women and health system implications for Australia. | Lancet Oncol | 2017 |
| 28593651 | Outcomes for patients with synchronous and metachronous primary lung cancer after diagnosis of head and neck cancer. | Head Neck | 2017 |
| 28720682 | Reducing Artifactual <i>EGFR</i> T790M Mutations in DNA from Formalin-Fixed Paraffin-Embedded Tissue by Use of Thymine-DNA Glycosylase. | Clin Chem | 2017 |
| 28843359 | Combination Osimertinib and Gefitinib in C797S and T790M EGFR-Mutated Non-Small Cell Lung Cancer. | J Thorac Oncol | 2017 |
| 28795492 | Treatment of ALK-rearranged non-small cell lung cancer: A review of the landscape and approach to emerging patterns of treatment resistance in the Australian context. | Asia Pac J Clin Oncol | 2017 |
| 27104612 | PD-L1 and Tumor Infiltrating Lymphocytes as Prognostic Markers in Resected NSCLC. | PLoS One | 2016 |
| 27753035 | Digital PCR of Genomic Rearrangements for Monitoring Circulating Tumour DNA. | Adv Exp Med Biol | 2016 |
| 27780599 | Calretinin but not caveolin-1 correlates with tumour histology and survival in malignant mesothelioma. | Pathology | 2016 |
| 27890503 | Lung cancer in 2016: immunotherapy comes of age. | Lancet Respir Med | 2016 |
| 27393503 | Temporal changes of EGFR mutations and T790M levels in tumour and plasma DNA following AZD9291 treatment. | Lung Cancer | 2016 |
| 27330807 | Progression-free and overall survival in ovarian cancer patients treated with CVac, a mucin 1 dendritic cell therapy in a randomized phase 2 trial. | J Immunother Cancer | 2016 |
| 27283865 | Combined BRAF and MEK inhibition in BRAF-mutant NSCLC. | Lancet Oncol | 2016 |
| 25722382 | Tecemotide in unresectable stage III non-small-cell lung cancer in the phase III START study: updated overall survival and biomarker analyses. | Ann Oncol | 2015 |
| 26453294 | Update on Mucin-1 immunotherapy in cancer: a clinical perspective. | Expert Opin Biol Ther | 2015 |
| 25913638 | Evolving treatment paradigms in lung cancer: role of immuno-oncology. | Asia Pac J Clin Oncol | 2015 |
| 23579358 | Feasibility of adding everolimus to carboplatin and paclitaxel, with or without bevacizumab, for treatment-naive, advanced non-small cell lung cancer. | Invest New Drugs | 2014 |
| 25429239 | Prevalence and natural history of ALK positive non-small-cell lung cancer and the clinical impact of targeted therapy with ALK inhibitors. | Clin Epidemiol | 2014 |
| 24995129 | A phase 2, single-arm study of an autologous dendritic cell treatment against mucin 1 in patients with advanced epithelial ovarian cancer. | J Immunother Cancer | 2014 |
| 24907066 | The Victorian Lung Cancer Registry pilot: improving the quality of lung cancer care through the use of a disease quality registry. | Lung | 2014 |
| 24569633 | A critical re-assessment of DNA repair gene promoter methylation in non-small cell lung carcinoma. | Sci Rep | 2014 |